vs
Healthpeak Properties（DOC）与百利高（PRGO）财务数据对比。点击上方公司名可切换其他公司
百利高的季度营收约是Healthpeak Properties的1.5倍（$1.1B vs $719.4M），Healthpeak Properties净利率更高（73.2% vs -127.8%，领先201.0%），Healthpeak Properties同比增速更快（3.1% vs -2.5%），Healthpeak Properties自由现金流更多（$357.0M vs $148.6M），过去两年Healthpeak Properties的营收复合增速更高（8.9% vs 1.3%）
Healthpeak Properties是美国医疗地产领域的房地产投资信托基金，核心投资范畴覆盖老年住宅、生命科学相关物业及医疗办公楼三类资产。公司2007年于马里兰州组建，总部设在科罗拉多州丹佛市，在尔湾、纳什维尔、旧金山均设有办事处，截至2019年12月31日共持有617处物业的权益。
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
DOC vs PRGO — 直观对比
营收规模更大
PRGO
是对方的1.5倍
$719.4M
营收增速更快
DOC
高出5.6%
-2.5%
净利率更高
DOC
高出201.0%
-127.8%
自由现金流更多
DOC
多$208.4M
$148.6M
两年增速更快
DOC
近两年复合增速
1.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $719.4M | $1.1B |
| 净利润 | $114.0M | $-1.4B |
| 毛利率 | — | 32.6% |
| 营业利润率 | 17.4% | -116.0% |
| 净利率 | 73.2% | -127.8% |
| 营收同比 | 3.1% | -2.5% |
| 净利润同比 | 2406.4% | -3093.9% |
| 每股收益（稀释后） | $0.16 | $-10.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOCPRGO
| Q4 25 | $719.4M | $1.1B | ||
| Q3 25 | $705.9M | $1.0B | ||
| Q2 25 | $694.3M | $1.1B | ||
| Q1 25 | $702.9M | $1.0B | ||
| Q4 24 | $698.0M | $1.1B | ||
| Q3 24 | $700.4M | $1.1B | ||
| Q2 24 | $695.5M | $1.1B | ||
| Q1 24 | $606.6M | $1.1B |
净利润DOCPRGO
| Q4 25 | $114.0M | $-1.4B | ||
| Q3 25 | $-117.1M | $7.5M | ||
| Q2 25 | $31.7M | $-8.4M | ||
| Q1 25 | $42.8M | $-6.4M | ||
| Q4 24 | $4.5M | $-44.4M | ||
| Q3 24 | $85.9M | $-21.0M | ||
| Q2 24 | $146.0M | $-108.4M | ||
| Q1 24 | $6.7M | $2.0M |
毛利率DOCPRGO
| Q4 25 | — | 32.6% | ||
| Q3 25 | 58.6% | 36.1% | ||
| Q2 25 | 60.2% | 34.4% | ||
| Q1 25 | 61.1% | 37.6% | ||
| Q4 24 | 60.3% | 33.9% | ||
| Q3 24 | 60.0% | 37.2% | ||
| Q2 24 | 60.6% | 37.0% | ||
| Q1 24 | 59.8% | 33.1% |
营业利润率DOCPRGO
| Q4 25 | 17.4% | -116.0% | ||
| Q3 25 | 9.2% | 7.0% | ||
| Q2 25 | 5.7% | 4.3% | ||
| Q1 25 | 7.7% | 4.5% | ||
| Q4 24 | -2.2% | 10.0% | ||
| Q3 24 | 14.1% | 7.4% | ||
| Q2 24 | 22.3% | -2.5% | ||
| Q1 24 | 3.7% | -5.1% |
净利率DOCPRGO
| Q4 25 | 73.2% | -127.8% | ||
| Q3 25 | -16.6% | 0.7% | ||
| Q2 25 | 4.6% | -0.8% | ||
| Q1 25 | 6.1% | -0.6% | ||
| Q4 24 | 0.7% | -3.9% | ||
| Q3 24 | 12.3% | -1.9% | ||
| Q2 24 | 21.0% | -10.2% | ||
| Q1 24 | 1.1% | 0.2% |
每股收益（稀释后）DOCPRGO
| Q4 25 | $0.16 | $-10.23 | ||
| Q3 25 | $-0.17 | $0.05 | ||
| Q2 25 | $0.05 | $-0.06 | ||
| Q1 25 | $0.06 | $-0.05 | ||
| Q4 24 | $0.02 | $-0.32 | ||
| Q3 24 | $0.12 | $-0.15 | ||
| Q2 24 | $0.21 | $-0.79 | ||
| Q1 24 | $0.01 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $467.5M | — |
| 总债务越低越好 | $9.8B | — |
| 股东权益账面价值 | $7.5B | $2.9B |
| 总资产 | $20.3B | $8.5B |
| 负债/权益比越低杠杆越低 | 1.31× | — |
8季度趋势，按日历期对齐
现金及短期投资DOCPRGO
| Q4 25 | $467.5M | — | ||
| Q3 25 | $91.0M | $432.1M | ||
| Q2 25 | $89.4M | $454.2M | ||
| Q1 25 | $70.6M | $409.9M | ||
| Q4 24 | $119.8M | $558.8M | ||
| Q3 24 | $180.4M | $1.5B | ||
| Q2 24 | $106.9M | $542.8M | ||
| Q1 24 | $101.8M | $658.5M |
总债务DOCPRGO
| Q4 25 | $9.8B | — | ||
| Q3 25 | $9.1B | — | ||
| Q2 25 | $9.0B | — | ||
| Q1 25 | $8.9B | — | ||
| Q4 24 | $8.7B | — | ||
| Q3 24 | $8.6B | — | ||
| Q2 24 | $8.6B | — | ||
| Q1 24 | $8.8B | — |
股东权益DOCPRGO
| Q4 25 | $7.5B | $2.9B | ||
| Q3 25 | $7.6B | $4.4B | ||
| Q2 25 | $7.9B | $4.5B | ||
| Q1 25 | $8.2B | $4.4B | ||
| Q4 24 | $8.4B | $4.3B | ||
| Q3 24 | $8.6B | $4.6B | ||
| Q2 24 | $8.8B | $4.5B | ||
| Q1 24 | $8.9B | $4.7B |
总资产DOCPRGO
| Q4 25 | $20.3B | $8.5B | ||
| Q3 25 | $19.6B | $10.1B | ||
| Q2 25 | $19.8B | $10.1B | ||
| Q1 25 | $19.8B | $9.8B | ||
| Q4 24 | $19.9B | $9.6B | ||
| Q3 24 | $20.0B | $11.2B | ||
| Q2 24 | $20.2B | $10.4B | ||
| Q1 24 | $20.5B | $10.6B |
负债/权益比DOCPRGO
| Q4 25 | 1.31× | — | ||
| Q3 25 | 1.20× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 1.04× | — | ||
| Q3 24 | 1.00× | — | ||
| Q2 24 | 0.98× | — | ||
| Q1 24 | 0.99× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.3B | $175.4M |
| 自由现金流经营现金流 - 资本支出 | $357.0M | $148.6M |
| 自由现金流率自由现金流/营收 | 49.6% | 13.4% |
| 资本支出强度资本支出/营收 | 124.4% | 2.4% |
| 现金转化率经营现金流/净利润 | 10.99× | — |
| 过去12个月自由现金流最近4个季度 | — | $145.1M |
8季度趋势，按日历期对齐
经营现金流DOCPRGO
| Q4 25 | $1.3B | $175.4M | ||
| Q3 25 | $315.0M | $51.7M | ||
| Q2 25 | $363.5M | $75.9M | ||
| Q1 25 | $279.4M | $-64.5M | ||
| Q4 24 | $1.1B | $312.6M | ||
| Q3 24 | $318.2M | $42.2M | ||
| Q2 24 | $316.2M | $9.5M | ||
| Q1 24 | $152.6M | $-1.4M |
自由现金流DOCPRGO
| Q4 25 | $357.0M | $148.6M | ||
| Q3 25 | — | $29.8M | ||
| Q2 25 | — | $56.7M | ||
| Q1 25 | — | $-90.0M | ||
| Q4 24 | $333.7M | $274.9M | ||
| Q3 24 | — | $15.1M | ||
| Q2 24 | — | $-18.9M | ||
| Q1 24 | — | $-26.5M |
自由现金流率DOCPRGO
| Q4 25 | 49.6% | 13.4% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | — | 5.4% | ||
| Q1 25 | — | -8.6% | ||
| Q4 24 | 47.8% | 24.2% | ||
| Q3 24 | — | 1.4% | ||
| Q2 24 | — | -1.8% | ||
| Q1 24 | — | -2.4% |
资本支出强度DOCPRGO
| Q4 25 | 124.4% | 2.4% | ||
| Q3 25 | — | 2.1% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | 105.6% | 3.3% | ||
| Q3 24 | — | 2.5% | ||
| Q2 24 | — | 2.7% | ||
| Q1 24 | — | 2.3% |
现金转化率DOCPRGO
| Q4 25 | 10.99× | — | ||
| Q3 25 | — | 6.89× | ||
| Q2 25 | 11.48× | — | ||
| Q1 25 | 6.52× | — | ||
| Q4 24 | 235.43× | — | ||
| Q3 24 | 3.71× | — | ||
| Q2 24 | 2.17× | — | ||
| Q1 24 | 22.85× | -0.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOC
暂无分部数据
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
